EFFECT OF BRIDGE REGION VARIATION ON ANTIFOLATE AND ANTITUMOR-ACTIVITY OF CLASSICAL 5-SUBSTITUTED 2,4-DIAMINOFURO[2,3-D]PYRIMIDINES

被引:82
作者
GANGJEE, A
DEVRAJ, R
MCGUIRE, JJ
KISLIUK, RL
机构
[1] ROSWELL PK CANC INST,GRACE CANC DRUG CTR,BUFFALO,NY 14263
[2] TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111
关键词
D O I
10.1021/jm00019a009
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Variation of the bridge linking the heterocyclic ring and p-aminobenzoyl-L-glutamate portions of our previously descibed classical 2,4-diaminofuro[2,3-d]pyrimidines 1 and 2 are reported as inhibitors of dihydrofolate reductase (DHFR) and thymidylate synthase (TS) and as antitumor agents. Specifically -CH2CH2- and -CH2NHCH2- bridged analogues, N-[4-[2-(2,4-diaminofuro[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid (3) and N-[4-[[N-[(2,4-diaminofuro[2,3-d]pyrimidin-5-yl)methyl]amino]methyl]benzoyl]-L-glutamic acid (4), respectively, were synthesized. Compound 3 was obtained via a Wittig reaction of the tributylphosphonium salt of 2,4-diamino-5-(chloromethyl)furo[2,3-d]pyrimidine (5) and methyl 4-formylbenzoate (6) followed by reduction and coupling with the diethyl ester of L-glutamic acid. Compound 4 was synthesized by the nucleophilic displacement of 5 with diethyl N-[4-( aminomethyl)benzoyl]-L-glutamate (15) and saponification. Both analogues were evaluated in vitro as inhibitors of DHFRs from (recombinant) human, human CCRF-CEM cells, and Lactobacillus casei. Compound 3 showed moderate activity (IC50 10(-6)-10( -7) M). Compound 4 was essentially inactive (IC50 10(-5) M, CCRF-CEM). The compounds were also evaluated against TS from (recombinant) human and L. casei and were of low activity (IC50 10(-6) M). The three-atom-bridged analogue 4 was somewhat more inhibitory to human TS than methotrexate (MTX). Compound 3 inhibited the growth of tumor cells in culture (IC50 10(-7) M) while 4 showed a low level of growth inhibitory activity. The inhibition of the growth of leukemia CCRF-CEM cells by both compounds parallels their inhibition of CCRF-CEM DHFR. Analogue 3 was a good substrate for human folylpolyglutamate synthetase (FPGS) derived from CCRF-CEM cells (K-m 8.5 mu M). Further evaluation of the growth inhibitory activity of 3 against the MTX-resistant subline of CCRF-CEM cells (R30dm) with decreased FPGS indicated that poly-gamma-glutamylation was important for its action. Protection studies with 3 in the FaDu squamous cell carcinoma cell line indicated that inhibition was completely reversed by leucovorin [(6R,S-6-formyltetrahydrofolate] or by a combination of thymidine and hypoxanthine, suggesting an antifolate effect directed at DHFR.
引用
收藏
页码:3798 / 3805
页数:8
相关论文
共 34 条
[1]  
ABRAHAM A, 1993, ADV EXP MED BIOL, V338, P421
[2]  
BARREDO J, 1992, MOL PHARMACOL, V42, P687
[3]   THE RENEWED POTENTIAL FOR FOLATE ANTAGONISTS IN CONTEMPORARY CANCER-CHEMOTHERAPY [J].
BERMAN, EM ;
WERBEL, LM .
JOURNAL OF MEDICINAL CHEMISTRY, 1991, 34 (02) :479-485
[4]  
Blakley R. L., 1984, FOLATES PTERINES, P191
[5]  
FOLEY GE, 1965, CANCER, V18, P522, DOI 10.1002/1097-0142(196504)18:4<522::AID-CNCR2820180418>3.0.CO
[6]  
2-J
[7]   CLASSICAL AND NONCLASSICAL FURO[2,3-D]PYRIMIDINES AS NOVEL ANTIFOLATES - SYNTHESIS AND BIOLOGICAL-ACTIVITIES [J].
GANGJEE, A ;
DEVRAJ, R ;
MCGUIRE, JJ ;
KISLIUK, RL ;
QUEENER, SF ;
BARROWS, LR .
JOURNAL OF MEDICINAL CHEMISTRY, 1994, 37 (08) :1169-1176
[8]  
JACKMAN AL, 1991, CANCER RES, V51, P5579
[9]  
JONES TR, 1981, EUR J CANCER, V17, P11
[10]   DIASTEREOISOMERS OF 5,10-METHYLENE-5,6,7,8-TETRAHYDROPTEROYL-D-GLUTAMIC ACID [J].
KISLIUK, RL ;
STRUMPF, D ;
GAUMONT, Y ;
LEARY, RP ;
PLANTE, L .
JOURNAL OF MEDICINAL CHEMISTRY, 1977, 20 (11) :1531-1533